| Source: DelveInsight Business Research LLP
New York, USA, Feb. 18, 2025 (GLOBE NEWSWIRE) — Global Allergy Diagnostics Market to Observe Growth at a CAGR of ~12% by 2032 | DelveInsight
The allergy diagnostics market is expanding rapidly due to the growing prevalence of allergic diseases. Additionally, worsening environmental conditions, including declining air quality in industrialized regions caused by rising pollution levels, are further driving market growth.
DelveInsight’s Allergy Diagnostics Market Insights report provides the current and forecast market analysis, individual leading allergy diagnostics companies’ market shares, challenges, allergy diagnostics market drivers, barriers, trends, and key market allergy diagnostics companies in the market.
Key Takeaways from the Allergy Diagnostics Market Report
To read more about the latest highlights related to the allergy diagnostics market, get a snapshot of the key highlights entailed in the Global Allergy Diagnostics Market Report
Allergy Diagnostics Overview
Allergy diagnostics play a crucial role in identifying specific allergens responsible for allergic reactions, enabling targeted management and treatment. These diagnostics include skin prick tests (SPT), blood tests measuring allergen-specific immunoglobulin E (IgE), and more advanced molecular techniques such as component-resolved diagnostics (CRD). Skin prick tests provide rapid results by introducing small amounts of allergens into the skin and observing localized reactions, while blood tests, such as enzyme-linked immunosorbent assays (ELISA) or radioallergosorbent tests (RAST), measure IgE levels to various allergens. CRD offers a more precise identification of allergenic proteins, helping distinguish between true allergies and cross-reactivities, which is particularly useful for food allergies and venom hypersensitivity.
Emerging technologies are further improving allergy diagnostics by increasing accuracy and reducing false positives. Basophil activation tests (BAT), for instance, assess immune cell responses to allergens, offering an alternative for patients who cannot undergo skin or blood tests. Microarray-based assays enable the simultaneous detection of multiple allergens, enhancing efficiency in clinical settings. Additionally, advancements in point-of-care diagnostics are making allergy testing more accessible and convenient, especially in remote areas. Personalized allergy diagnostics, integrating genetic and immunological markers, are also on the horizon, promising more precise and individualized allergy management strategies.
Allergy Diagnostics Market Insights
North America is projected to hold a significant share of the allergy diagnostics market throughout the forecast period. This dominance can be attributed to the rising prevalence of allergies in the region. Furthermore, North America exhibits a high level of awareness regarding allergies of different causes. The presence of leading market players and well-established centers specializing in allergy and immunology services further drives the adoption of allergy diagnostic products.
For example, the increasing cases of allergies, including food allergies, drug allergies, and hay fever, along with a growing number of manufacturers in the United States, are expected to drive demand for allergy diagnostics, contributing to the market’s expansion in the region. DelveInsight’s analysts estimate that 57.5 million prevalent cases of food allergy were found in 2023 in the 7MM. The analysis suggests that around 58% of all food allergy cases across the 7MM were located in the United States.
Additionally, advancements in product development, regulatory approvals, and strategic collaborations are anticipated to further propel the United States allergy diagnostics market in the coming years. Consequently, these combined factors are likely to accelerate market growth during the forecast period.
To know more about why North America is leading the market growth in the allergy diagnostics market, get a snapshot of the Allergy Diagnostics Market Outlook
Allergy Diagnostics Market Dynamics
The allergy diagnostics market is experiencing significant growth, driven by rising allergy prevalence, advancements in diagnostic technologies, and increasing awareness among healthcare providers and patients. Allergic diseases, including asthma, rhinitis, and food allergies, are on the rise globally due to environmental pollution, changing lifestyles, and genetic predispositions. This increasing disease burden is pushing the demand for accurate and early diagnostic solutions, which, in turn, is fueling market expansion.
Technological advancements, particularly in molecular diagnostics and automated immunoassay platforms, have revolutionized allergy testing. Traditional skin prick tests and blood tests are now supplemented by highly specific and sensitive multiplex assays, which allow simultaneous detection of multiple allergens with minimal sample volumes. This progress is enhancing diagnostic accuracy and efficiency, making allergy diagnostics more accessible and reliable. The shift towards personalized medicine is also influencing market trends, as physicians increasingly seek targeted diagnostic tools to develop customized treatment plans for patients.
Regulatory policies and reimbursement frameworks play a crucial role in shaping the allergy diagnostics market. In many regions, stringent regulatory approvals and varying reimbursement structures impact market penetration and adoption rates. While developed markets such as North America and Europe have well-established healthcare infrastructures supporting allergy diagnostics, emerging economies face challenges related to affordability, access, and awareness. However, increasing healthcare expenditure and government initiatives in countries like China and India are expected to bridge this gap over time.
Competition in the market is intensifying with key players focusing on research and development to introduce innovative diagnostic solutions. Companies are investing in next-generation sequencing, microarray technologies, and AI-driven diagnostic tools to gain a competitive edge. Mergers, acquisitions, and strategic collaborations are also shaping the market landscape, enabling firms to expand their product portfolios and geographical presence. The rising adoption of point-of-care testing solutions further indicates a shift towards decentralized and home-based allergy diagnostics.
Overall, the allergy diagnostics market is poised for robust growth, driven by rising disease prevalence, technological innovation, and increasing healthcare investments. While challenges such as regulatory hurdles and affordability remain, ongoing advancements in diagnostic techniques and a growing emphasis on early disease detection are expected to propel the market forward in the coming years.
Get a sneak peek at the allergy diagnostics market dynamics @ Allergy Diagnostics Market Dynamics Analysis
Allergy Diagnostics Market Assessment
Which MedTech key players in the allergy diagnostics market are set to emerge as the trendsetter explore @ Allergy Diagnostics Companies
Table of Contents
Interested in knowing the allergy diagnostics market by 2032? Click to get a snapshot of the Allergy Diagnostics Market Trends
Related Reports
Allergy Diagnostics & Therapeutics Market
Allergy Diagnostics & Therapeutics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key allergy diagnostics & therapeutics companies, including Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher, Canon Inc., Minaris Medical America, Inc., Eurofins Scientific, Allergy Therapeutics, GSK plc, HAL Allergy Group, Bayer AG, Novartis AG, Merck & Co., Inc., Sanofi, Omega Diagnostics Ltd, Romer Labs Division Holding, Neogen Corporation, Pfizer Inc., R-Biopharm AG, Lincoln Diagnostics, Inc., Astra Biotech GmbH, among others.
Food Allergy Market
Food Allergy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Food Allergy companies, including Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, among others.
Food Allergy Pipeline
Food Allergy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key food allergy companies, including Merck & Co, DBV technologies, Genentech, Camallergy, Regeneron Pharmaceuticals, InnoUp Farma, Aravax, Inimmune, Novartis Pharmaceuticals, Astrazeneca, Cour Pharmaceuticals, Siolta Therapeutics, Vedanta Biosciences, Mabylon, GI Innovation, among others.
Peanut Allergy Market
Peanut Allergy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key peanut allergy companies including Vedanta Biosciences, Inc., Allergy Therapeutics, COUR Pharmaceutical Development Company, Inc., ALK-Abelló A/S, Syneos Health, DBV Technologies, Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), Alladapt Immunotherapeutics, Inc., among others.
Peanut Allergy Pipeline
Peanut Allergy Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peanut allergy companies, including DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Français 
English